Wird geladen...
Erlotinib in combination with bevacizumab and FOLFOX4 as second-line chemotherapy for patients with metastatic colorectal cancer
Background: We conducted a phase II study by combining FOLFOX4 plus bevacizumab (BV) with erlotinib (ER) as second-line chemotherapy for patients with metastatic colorectal cancer (mCRC). Methods: Patients were divided into two groups in randomized double-blind manner. One group was given FOLFOX4 pl...
Gespeichert in:
| Veröffentlicht in: | Am J Cancer Res |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
e-Century Publishing Corporation
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5622230/ https://ncbi.nlm.nih.gov/pubmed/28979818 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|